Leishmaniasis is a rare disease in Central Europe and is diagnosed almost exclusively in travellers or migrants coming from tropical or subtropical countries. We conducted an explorative cross-sectional serological study, using a commercial ELISA, in 1048 healthy Austrian individuals to assess the distribution of specific antibodies against Leishmania spp. in humans in Austria. Overall, 47 individuals (4.5%) tested positive, and an additional 32 (3.1%) showed borderline results. After 12 months, sera from 42 of the 79 individuals who had initially tested seropositive/borderline were tested by ELISA a second time: 18 were persistently positive, nine were borderline. Those whose sera were persistently positive/borderline were then screened for potential carrier status using a commercial oligochromatographic PCR test to detect parasite DNA. Four samples were PCR positive and were subjected to a second PCR allowing parasite identification after DNA sequencing: two samples were identified as Leishmania donovani/infantum complex and Leishmania (Viannia) guyanensis, respectively. Epidemiological information was obtained with a questionnaire: no correlation was found for the number of holiday trips within the previous 6 months, but a significant risk of exposure to Leishmania spp. was found for travel to the New World, particularly to the Caribbean. Our data demonstrate that Leishmania spp. seroprevalence in non-endemic countries has been considerably underestimated.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.